Syngene International Expands Capabilities
Syngene International, a global contract research, development and manufacturing organization (CRDMO), announces plans to add a GMP bioconjugation suite.
This new capability will complement commercial payload, linker and monoclonal antibodies services, enabling Syngene to offer fully integrated, end-to-end services for antibody-drug conjugates (ADCs) – from discovery through to GMP manufacturing.
Author's summary: Syngene International expands ADC capabilities.
More News
- Roblox "strongly contests" Iraqi ban, claims the government's reasoning is "inaccurate"
- MacroCycle found a shortcut for plastic recycling — catch it at TechCrunch Disrupt 2025 | TechCrunch
- Flyers send Jett Luchanko back to juniors as development takes priority | NorthPennNow
- Biofuels and ethanol key to the future of U.S. agriculture - High Plains Journal
- Huber Advanced Materials Announces Price Increase for All Product Lines
- Following Misconduct Complaint, Supervisor Bushnell Hires Private Attorney to Challenge the County’s Investigation Process
- TFSA Million Dollar Blueprint: The Only Canadian Stock You'll Need
- Waymo co-CEO on robotaxi vandalism: 'We're not standing for it' | TechCrunch
- Sweden’s still ahead in the preparedness game — and now it means business
- Egyptian journalist Ismail Alexandrani held for past month - one month too many!